ScoreWhy is Swedish Orphan Biovitrum AB ?
1
Healthy long term growth as Net Sales has grown by an annual rate of 13.10%
2
With a growth in Net Profit of 50.63%, the company declared Very Positive results in Mar 26
- The company has declared positive results for the last 7 consecutive quarters
- RAW MATERIAL COST(Y) Fallen by -5.37% (YoY)
- DEBTORS TURNOVER RATIO(HY) Highest at 3.59 times
- PRE-TAX PROFIT(Q) At SEK 1,834 MM has Grown at 54.38%
3
With ROE of 19.95%, it has a expensive valuation with a 3.63 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 69.55%, its profits have risen by 85.8% ; the PEG ratio of the company is 0.2
4
Consistent Returns over the last 3 years
- Along with generating 69.55% returns in the last 1 year, the stock has outperformed OMX Stockholm 30 in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Swedish Orphan Biovitrum AB should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Swedish Orphan Biovitrum AB for you?
Medium Risk, High Return
Absolute
Risk Adjusted
Volatility
Swedish Orphan Biovitrum AB
69.55%
97.14
28.51%
OMX Stockholm 30
30.13%
1.89
15.95%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
13.10%
EBIT Growth (5y)
12.54%
EBIT to Interest (avg)
6.87
Debt to EBITDA (avg)
1.73
Net Debt to Equity (avg)
0.33
Sales to Capital Employed (avg)
0.48
Tax Ratio
12.54%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.02%
ROE (avg)
10.77%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
18
Industry P/E
Price to Book Value
3.63
EV to EBIT
18.26
EV to EBITDA
8.10
EV to Capital Employed
3.07
EV to Sales
5.20
PEG Ratio
0.21
Dividend Yield
NA
ROCE (Latest)
16.80%
ROE (Latest)
19.95%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend10What is working for the Company
RAW MATERIAL COST(Y)
Fallen by -5.37% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 3.59 times
PRE-TAX PROFIT(Q)
At SEK 1,834 MM has Grown at 54.38%
NET PROFIT(Q)
At SEK 1,427.23 MM has Grown at 50.48%
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Swedish Orphan Biovitrum AB
Pre-Tax Profit
At SEK 1,834 MM has Grown at 54.38%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (SEK MM)
Net Profit
At SEK 1,427.23 MM has Grown at 50.48%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (SEK MM)
Debtors Turnover Ratio
Highest at 3.59 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -5.37% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
